Alberto LleÃ³

List of Publications by Year
in descending order

279 papers	20,974 citations	23567 58 h-index	13379 130 g-index
306 all docs	306 docs citations	306 times ranked	22627 citing authors

#	Article	IF	Citations
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
3	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
4	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
5	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
6	TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Science Translational Medicine, 2014, 6, 243ra86.	12.4	600
7	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
8	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early‐stage Alzheimer's disease and associate with neuronal injury markers. EMBO Molecular Medicine, 2016, 8, 466-476.	6.9	392
9	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
10	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
11	A multicentre validation study of the diagnostic value of plasma neurofilament light. Nature Communications, 2021, 12, 3400.	12.8	219
12	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. World Journal of Biological Psychiatry, 2018, 19, 244-328.	2.6	215
13	Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nature Medicine, 2004, 10, 1065-1066.	30.7	206
14	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
15	Consensus guidelines for lumbar puncture in patients with neurological diseases. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 111-126.	2.4	197
16	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiology of Aging, 2010, 31, 725-731.	3.1	196
17	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. Lancet Neurology, The, 2018, 17, 64-74.	10.2	195
18	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimer's and Dementia, 2016, 12, 154-163.	0.8	179

#	ARTICLE	IF	CITATIONS
19	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. Science Translational Medicine, 2019, 11, .	12.4	170
20	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet, The, 2020, 395, 1988-1997.	13.7	164
21	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. Nature Reviews Neurology, 2015, 11, 41-55.	10.1	144
22	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid Aβ42 Levels in Cognitively Normal Elderly. Sleep, 2016, 39, 2041-2048.	1.1	140
23	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet Neurology, The, 2018, 17, 860-869.	10.2	140
24	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
25	Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein. Journal of Neuroscience, 2005, 25, 3009-3017.	3.6	139
26	Confluence of α-Synuclein, Tau, and β-Amyloid Pathologies in Dementia With Lewy Bodies. Journal of Neuropathology and Experimental Neurology, 2013, 72, 1203-1212.	1.7	138
27	Qualitative changes in human γ-secretase underlie familial Alzheimer's disease. Journal of Experimental Medicine, 2015, 212, 2003-2013.	8.5	134
28	Inflammatory biomarkers in Alzheimer's disease plasma. Alzheimer's and Dementia, 2019, 15, 776-787.	0.8	134
29	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
30	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. Neurology, 2015, 85, 626-633.	1.1	131
31	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. Journal of Alzheimer's Disease, 2017, 57, 483-491.	2.6	126
32	Dementia Risk in Parkinson Disease. Archives of Neurology, 2011, 68, 359-64.	4.5	125
33	Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimer's and Dementia, 2018, 14, 340-351.	0.8	122
34	Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy. PLoS ONE, 2011, 6, e26609.	2.5	115
35	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. Molecular and Cellular Proteomics, 2019, 18, 546-560.	3.8	115
36	Cerebrospinal fluid β-amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. Annals of Neurology, 2014, 76, 223-230.	5.3	110

#	Article	IF	Citations
37	Pittsburgh compound B imaging and cerebrospinal fluid amyloid-β in a multicentre European memory clinic study. Brain, 2016, 139, 2540-2553.	7.6	107
38	Relationship Between β-Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 157-167.	2.6	106
39	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. Annals of Clinical and Translational Neurology, 2019, 6, 1815-1824.	3.7	104
40	Frequency of Mutations in the Presenilin and Amyloid Precursor Protein Genes in Early-Onset Alzheimer Disease in Spain. Archives of Neurology, 2002, 59, 1759.	4.5	103
41	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathologica, 2013, 125, 201-213.	7.7	103
42	CSF sAPPβ, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology, 2017, 89, 178-188.	1.1	100
43	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. Journal of Neuroinflammation, 2017, 14, 118.	7.2	99
44	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	9.0	97
45	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. Neurobiology of Aging, 2014, 35, 444.e1-444.e4.	3.1	92
46	<i>APOE</i>-by-sex interactions on brain structure and metabolism in healthy elderly controls. Oncotarget, 2015, 6, 26663-26674.	1.8	92
47	Synaptic phosphorylated α-synuclein in dementia with Lewy bodies. Brain, 2017, 140, 3204-3214.	7.6	90
48	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. Alzheimer's and Dementia, 2019, 15, 644-654.	0.8	90
49	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. Brain, 2020, 143, 3776-3792.	7.6	89
50	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. Human Mutation, 2017, 38, 297-309.	2.5	87
51	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology, 2021, 96, e671-e683.	1.1	84
52	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. Alzheimer's and Dementia, 2019, 15, 742-753.	0.8	82
53	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiology of Aging, 2015, 36, 2018-2023.	3.1	75
54	Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations. American Journal of Geriatric Psychiatry, 2004, 12, 146-156.	1.2	73

#	Article	IF	Citations
55	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. Nature Communications, 2019, 10, 4766.	12.8	73
56	A metaboliteâ€based machine learning approach to diagnose Alzheimerâ€type dementia in blood: Results from the European Medicalâ€‰Information Framework for Alzheimer disease biomarker discovery cohort. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 933-938.	3.7	70
57	Activity of &#947; -Secretase on Substrates Other than APP. Current Topics in Medicinal Chemistry, 2008, 8, 9-16.	2.1	67
58	Non-Fibrillar Oligomeric Amyloid-Î² within Synapses. Journal of Alzheimer's Disease, 2016, 53, 787-800.	2.6	65
59	Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 499-509.	0.8	65
60	Neuropsychological deficits in patients with cognitive complaints after COVIDâ€19. Brain and Behavior, 2022, 12, e2508.	2.2	64
61	Current Therapeutic Options for Alzheimers Disease. Current Genomics, 2007, 8, 550-558.	1.6	63
62	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. Alzheimer's Research and Therapy, 2018, 10, 64.	6.2	62
63	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimer's and Dementia, 2019, 15, 817-827.	0.8	62
64	Mild cholesterol depletion reduces amyloidâ€Î² production by impairing APP trafficking to the cell surface. Journal of Neurochemistry, 2009, 110, 220-230.	3.9	60
65	CSF sAPPÎ², YKL-40, and NfL along the ALS-FTD spectrum. Neurology, 2018, 91, e1619-e1628.	1.1	59
66	PLD3 in non-familial Alzheimer's disease. Nature, 2015, 520, E3-E5.	27.8	58
67	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.8	58
68	Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (APP) for Î³-Secretase. Journal of Biological Chemistry, 2005, 280, 27303-27309.	3.4	57
69	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. Oncotarget, 2018, 9, 34691-34698.	1.8	57
70	Analysis of the<i>CHCHD10</i>gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. Brain, 2015, 138, e400-e400.	7.6	56
71	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. Alzheimer's and Dementia, 2015, 11, 195.	0.8	56
72	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. Journal of Clinical Sleep Medicine, 2018, 14, 1725-1733.	2.6	56

#	Article	IF	Citations
73	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 26.	6.2	56
74	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 684-691.	1.9	55
75	Use of amyloid-PET to determine cutpoints for CSF markers. Neurology, 2016, 86, 50-58.	1.1	54
76	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. JAMA Neurology, 2018, 75, 738.	9.0	54
77	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2020, 7, .	6.0	54
78	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. Journal of Alzheimer's Disease, 2014, 39, 719-726.	2.6	53
79	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. Acta Neuropathologica, 2017, 134, 475-487.	7.7	53
80	GBA and APOE Îµ4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	3.3	53
81	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. Journal of Neuropathology and Experimental Neurology, 2010, 69, 53-59.	1.7	52
82	Nanoscale structure of amyloid-Î² plaques in Alzheimer's disease. Scientific Reports, 2019, 9, 5181.	3.3	52
83	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. Annals of Neurology, 2017, 82, 247-258.	5.3	51
84	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. Oncotarget, 2017, 8, 104706-104716.	1.8	51
85	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. Journal of Alzheimer's Disease, 2015, 48, S87-S98.	2.6	50
86	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. Nature Neuroscience, 2019, 22, 1258-1268.	14.8	48
87	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal-dominant Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 1251-1260.	0.8	47
88	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. JAMA Network Open, 2022, 5, e2212910.	5.9	47
89	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. Alzheimer's and Dementia, 2019, 15, 1478-1488.	0.8	46
90	Notch1 Competes with the Amyloid Precursor Protein for Î³-Secretase and Down-regulates Presenilin-1 Gene Expression. Journal of Biological Chemistry, 2003, 278, 47370-47375.	3.4	45

#	Article	IF	Citations
91	MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies. Neurobiology of Aging, 2013, 34, 936-942.	3.1	45
92	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease€. Human Molecular Genetics, 2015, 24, 2023-2034.	2.9	45
93	Regional Overlap of Pathologies in Lewy Body Disorders. Journal of Neuropathology and Experimental Neurology, 2017, 76, 216-224.	1.7	45
94	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. Molecular Neurobiology, 2017, 54, 6647-6654.	4.0	45
95	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. Brain, 2019, 142, 1121-1133.	7.6	45
96	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the <i>C9orf72</i> expansion mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 162-168.	1.9	44
97	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 597-609.	3.7	44
98	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. Clinical Chemistry and Laboratory Medicine, 2022, 60, 207-219.	2.3	44
99	&#947;-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2011, 11, 1513-1527.	2.1	43
100	Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. Journal of Alzheimer's Disease, 2016, 50, 1-7.	2.6	43
101	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Translational Psychiatry, 2020, 10, 403.	4.8	42
102	Cortical microstructural correlates of astrocytosis in autosomal-dominant Alzheimer disease. Neurology, 2020, 94, e2026-e2036.	1.1	42
103	Homocysteine and Cognitive Impairment. Dementia and Geriatric Cognitive Disorders, 2008, 26, 506-512.	1.5	41
104	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid-β Peptide Aggregation. Journal of Alzheimer's Disease, 2014, 40, 643-657.	2.6	41
105	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. Alzheimer's Research and Therapy, 2018, 10, 30.	6.2	40
106	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 70-77.	1.9	40
107	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 710-717.	4.3	39
108	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	7.6	39

#	Article	IF	Citations
109	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. Journal of Alzheimer's Disease, 2016, 50, 539-546.	2.6	38
110	Challenges associated with biomarker–based classification systems for Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 346-357.	2.4	37
111	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. Frontiers in Neurology, 2015, 6, 216.	2.4	36
112	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2020, 87, 139.e1-139.e7.	3.1	35
113	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. Neurobiology of Aging, 2014, 35, 2657.e13-2657.e19.	3.1	34
114	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. Neurobiology of Aging, 2015, 36, 2005.e15-2005.e22.	3.1	34
115	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. Neurobiology of Aging, 2016, 46, 236.e1-236.e6.	3.1	34
116	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, 1329-1341.	0.8	34
117	Early-Onset Familial Lewy Body Dementia With Extensive Tauopathy: A Clinical, Genetic, and Neuropathological Study. Journal of Neuropathology and Experimental Neurology, 2009, 68, 73-82.	1.7	33
118	Autosomal–dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production. Journal of Neurochemistry, 2014, 128, 330-339.	3.9	33
119	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. Scientific Reports, 2019, 9, 7803.	3.3	33
120	Cerebrospinal fluid A beta 1–40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. Alzheimer's Research and Therapy, 2020, 12, 123.	6.2	33
121	State–of–the–art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. Alzheimer's and Dementia, 2022, 18, 159-177.	0.8	33
122	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. Nature Communications, 2021, 12, 4304.	12.8	33
123	Association of Apolipoprotein E É›4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. JAMA Neurology, 2021, 78, 937.	9.0	32
124	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. Translational Neurodegeneration, 2021, 10, 50.	8.0	32
125	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. Neurobiology of Aging, 2015, 36, 2587-2596.	3.1	30
126	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. Developmental Neurobiology, 2019, 79, 716-737.	3.0	30

#	ARTICLE	IF	CITATIONS
127	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. Sleep, 2019, 42, .	1.1	30
128	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1206-1214.	1.9	30
129	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimerâ€™s disease. Molecular Neurodegeneration, 2022, 17, 27.	10.8	30
130	Heritability and genetic variance of dementia with Lewy bodies. Neurobiology of Disease, 2019, 127, 492-501.	4.4	29
131	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. Lancet Neurology, The, 2021, 20, 605-614.	10.2	29
132	Diagnostic and Prognostic Value ofÂtheÂCombination of Two Measures ofÂVerbal Memory in Mild Cognitive Impairment dueÂto Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2017, 58, 909-918.	2.6	28
133	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. Scientific Reports, 2017, 7, 2477.	3.3	28
134	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. Frontiers in Aging Neuroscience, 2018, 10, 409.	3.4	28
135	APOE Îµ4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 65.	6.2	28
136	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	3.1	27
137	Biphasic cortical macroâ€•and microstructural changes in autosomal dominant Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 618-628.	0.8	27
138	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. Scientific Reports, 2020, 10, 4308.	3.3	26
139	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2022, 18, 1868-1879.	0.8	26
140	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 73, 1585-1595.	2.6	25
141	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. Neurobiology of Aging, 2017, 53, 192.e1-192.e4.	3.1	24
142	Detection of amyloid beta peptides in body fluids for the diagnosis of alzheimerâ€™s disease: Where do we stand?. Critical Reviews in Clinical Laboratory Sciences, 2020, 57, 99-113.	6.1	24
143	Active bilingualism delays the onset of mild cognitive impairment. Neuropsychologia, 2020, 146, 107528.	1.6	24
144	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. Alzheimer's and Dementia, 2021, 17, 1628-1640.	0.8	23

#	Article	IF	Citations
145	Acetylcholinesterase Modulates Presenilin-1 Levels and γ-Secretase Activity. Journal of Alzheimer's Disease, 2014, 41, 911-924.	2.6	22
146	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.8	22
147	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	3.1	21
148	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. Molecular Neurodegeneration, 2020, 15, 46.	10.8	21
149	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. Frontiers in Aging Neuroscience, 2022, 14, 840651.	3.4	20
150	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. Neurobiology of Aging, 2018, 66, 181.e3-181.e10.	3.1	19
151	Cortical microstructure in the amyotrophic lateral sclerosis–frontotemporal dementia continuum. Neurology, 2020, 95, e2565-e2576.	1.1	19
152	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. International Journal of Geriatric Psychiatry, 2021, 36, 324-333.	2.7	19
153	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. Clinica Chimica Acta, 2019, 491, 81-84.	1.1	18
154	Annexin A5 prevents amyloid-β-induced toxicity in choroid plexus: implication for Alzheimer's disease. Scientific Reports, 2020, 10, 9391.	3.3	18
155	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. Journal of Alzheimer's Disease, 2021, 81, 629-640.	2.6	18
156	The $A\beta1$–$42/A\beta1$–40 ratio in CSF is more strongly associated to tau markers and clinical progression than $A\beta1$–42 alone. Alzheimer's Research and Therapy, 2022, 14, 20.	6.2	18
157	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. JAMA Network Open, 2022, 5, e229588.	5.9	18
158	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. Clinica Chimica Acta, 2019, 490, 98-101.	1.1	17
159	Elevated YKL-40 and low $sAPP\beta$:YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 180-186.	1.9	17
160	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. Alzheimer's and Dementia, 2021, 17, 605-617.	0.8	17
161	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. Journal of Alzheimer's Disease, 2018, 64, 505-513.	2.6	16
162	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. Frontiers in Aging Neuroscience, 2021, 13, 712545.	3.4	16

#	ARTICLE	IF	CITATIONS
163	Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. Neuroscience Letters, 2002, 318, 166-168.	2.1	15
164	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. Neurobiology of Aging, 2018, 69, 293.e9-293.e11.	3.1	15
165	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimerâ€™s Disease in Subjects with Down Syndrome. Journal of Alzheimer's Disease, 2016, 55, 1489-1496.	2.6	14
166	New developments of biofluidâ€based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. Alzheimer's and Dementia, 2022, 18, 2292-2307.	0.8	14
167	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016, 171, 175-180.	1.7	13
168	APPâ€derived peptides reflect neurodegeneration in frontotemporal dementia. Annals of Clinical and Translational Neurology, 2019, 6, 2518-2530.	3.7	13
169	A comprehensive screening of copy number variability in dementia with Lewy bodies. Neurobiology of Aging, 2019, 75, 223.e1-223.e10.	3.1	13
170	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimerâ€™s Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	2.6	13
171	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.8	13
172	Establishing In-House Cutoffs of CSF Alzheimerâ€™s Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. International Journal of Molecular Sciences, 2022, 23, 6891.	4.1	13
173	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. Neurobiology of Aging, 2017, 49, 214.e13-214.e15.	3.1	12
174	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	2.6	12
175	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid-β positivity. Cortex, 2019, 121, 117-124.	2.4	12
176	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. JAMA Network Open, 2021, 4, e211290.	5.9	12
177	Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 1828-1835.	6.4	11
178	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species. NeuroImage: Clinical, 2018, 20, 603-610.	2.7	11
179	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. Neurobiology of Disease, 2019, 124, 428-438.	4.4	11
180	AMYQ: An index to standardize quantitative amyloid load across PET tracers. Alzheimer's and Dementia, 2021, 17, 1499-1508.	0.8	11

#	ARTICLE	IF	CITATIONS
181	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimerâ€™s Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	2.6	10
182	Cortical microstructure in primary progressive aphasia: a multicenter study. Alzheimer's Research and Therapy, 2022, 14, 27.	6.2	10
183	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. Neurobiology of Aging, 2014, 35, 1526-1536.	3.1	9
184	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimerâ€™s disease. Molecular Neurodegeneration, 2016, 11, 66.	10.8	9
185	Assessing the role of TUBA4A gene in frontotemporal degeneration. Neurobiology of Aging, 2016, 38, 215.e13-215.e14.	3.1	9
186	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to earlyâ€onset Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 99-111.	2.4	9
187	CSF Proteomic Alzheimerâ€™s Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. Proteomes, 2021, 9, 36.	3.5	9
188	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. PLoS ONE, 2022, 17, e0267298.	2.5	9
189	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. Alzheimer Disease and Associated Disorders, 2015, 29, 353-356.	1.3	8
190	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. Frontiers of Neurology and Neuroscience, 2016, 39, 117-123.	2.8	8
191	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. Neurobiology of Aging, 2018, 64, 58-67.	3.1	8
192	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. Neurobiology of Aging, 2021, 99, 99.e15-99.e22.	3.1	8
193	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. Neurobiology of Aging, 2021, 103, 158.e1-158.e5.	3.1	8
194	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimerâ€™s disease. Translational Neurodegeneration, 2021, 10, 37.	8.0	8
195	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. Cells, 2020, 9, 1252.	4.1	8
196	Kidins220 Correlates with Tau inÂAlzheimerâ€™s Disease Brain andÂCerebrospinal Fluid. Journal of Alzheimer's Disease, 2016, 55, 1327-1333.	2.6	7
197	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12052.	2.4	7
198	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	2.6	7

#	ARTICLE	IF	CITATIONS
199	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. BMJ Open Diabetes Research and Care, 2020, 8, e001516.	2.8	7
200	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. Aphasiology, 2021, 35, 240-266.	2.2	7
201	Biomarkers in neurological disorders: a fast-growing market. Brain Communications, 2021, 3, fcab086.	3.3	7
202	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. Annals of Neurology, 2021, 90, 407-416.	5.3	7
203	Sex-Specific Metabolic Pathways Were Associated with Alzheimerâ€™s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. Biomedicines, 2021, 9, 1610.	3.2	7
204	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. Journal of Neural Transmission, 2022, 129, 231-237.	2.8	7
205	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. Molecular Neurodegeneration, 2022, 17, 29.	10.8	7
206	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. Alzheimer's and Dementia, 2021, 17, .	0.8	7
207	Dementia and epilepsy. Neurology, 2020, 95, 1074-1075.	1.1	6
208	Race and Alzheimer Disease Biomarkers. Neurology: Genetics, 2021, 7, e574.	1.9	6
209	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. Alzheimer's Research and Therapy, 2021, 13, 119.	6.2	6
210	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. Frontiers in Neurology, 2021, 12, 750543.	2.4	6
211	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimerâ€™s Disease Risk. Journal of Alzheimer's Disease, 2017, 56, 1065-1074.	2.6	5
212	The pitfalls of biomarkerâ€boased classification schemes. Alzheimer's and Dementia, 2017, 13, 1072-1074.	0.8	5
213	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. Multiple Sclerosis Journal, 2019, 25, 1535-1538.	3.0	5
214	White Matter Hyperintensities Are No Major Confounder for Alzheimerâ€™s Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	2.6	5
215	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimerâ€™s disease, but not in cerebral amyloid angiopathy. Alzheimer's Research and Therapy, 2021, 13, 160.	6.2	5
216	O5â€02â€04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMERâ€™S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2016, 12, P380.	0.8	4

#	Article	IF	Citations
217	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. Dementia and Geriatric Cognitive Disorders, 2018, 45, 220-231.	1.5	4
218	Evaluation of biochemical and hematological parameters in adults with Down syndrome. Scientific Reports, 2020, 10, 13755.	3.3	4
219	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. Alzheimer's and Dementia, 2021, 17, .	0.8	4
220	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. Clinical Chemistry and Laboratory Medicine, 2022, 60, 1058-1063.	2.3	4
221	Myelin loss in <i>C9orf72</i> hexanucleotide expansion carriers. Journal of Neuroscience Research, 2022, 100, 1862-1875.	2.9	4
222	[O3â€"10â€"03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. Alzheimer's and Dementia, 2017, 13, P924.	0.8	3
223	El Alzheimer, la enfermedad ignorada. Medicina ClÃnica, 2018, 150, 432-433.	0.6	3
224	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
225	Effect of <scp><i>REST</i></scp> on brain metabolism in the Alzheimer disease continuum. Annals of Neurology, 2015, 78, 661-662.	5.3	2
226	Alzheimer's disease: An ignored condition. Medicina ClÃnica (English Edition), 2018, 150, 432-433.	0.2	2
227	Amyloid imaging in depression: a predictor of Alzheimer's disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 711-713.	6.4	1
228	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
229	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
230	P1â€"277: CORRELATION BETWEEN INNOTESTÂ® AND THE FULLY AUTOMATED LUMIPULSEÂ® G PLATFORM FOR THE ANALYSIS OF Î²â€"AMYLOID 1â€"42 AND TOTAL TAU. Alzheimer's and Dementia, 2018, 14, P388.	0.8	1
231	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. Alzheimer's and Dementia, 2020, 16, e036954.	0.8	1
232	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e047209.	0.8	1
233	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. Clinical Nuclear Medicine, 2020, 45, e239-e240.	1.3	1
234	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	1

#	Article	IF	Citations
235	Calsynteninâ€1 is a cerebrospinal fluid marker of frontotemporal dementiaâ€related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.8	1
236	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.8	1
237	P3-230: CSF Î²-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
238	IC-P-217: CSF Î²-AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
239	P1-121: Comparison of different ÃŸ-amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
240	P4â€122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimerâ€™s Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.8	0
241	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
242	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
243	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0
244	[O1â€06â€02]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER's DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS. Alzheimer's and Dementia, 2017, 13, P201.	0.8	0
245	[P1â€366]: WEIGHT LOSS MIGHT BE A NONâ€COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.8	0
246	[P3â€274]: STRUCTURAL CORRELATES OF ALZHEIMER's DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.8	0
247	[P1â€238]: THE SAPPÎ²/YKLâ€40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	0.8	0
248	[P1â€289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.8	0
249	[P2â€259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR ADâ€RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P712.	0.8	0
250	P3â€233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.8	0
251	P4â€076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1463.	0.8	0
252	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.8	0

#	Article	IF	Citations
253	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. Alzheimer's and Dementia, 2018, 14, P777.	0.8	0
254	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. Alzheimer's and Dementia, 2018, 14, P1248.	0.8	0
255	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. Alzheimer's and Dementia, 2018, 14, P1648.	0.8	0
256	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAS AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. Alzheimer's and Dementia, 2018, 14, P398.	0.8	0
257	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P1515.	0.8	0
258	ICâ€Pâ€148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P119.	0.8	0
259	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2019, 15, P558.	0.8	0
260	AmyQ: An index to accurately measure cerebral amyloid load. Alzheimer's and Dementia, 2020, 16, e039735.	0.8	0
261	Oligodendroglial alterations in FTD caused by C9orf72 expansion. Alzheimer's and Dementia, 2020, 16, e040196.	0.8	0
262	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. Alzheimer's and Dementia, 2020, 16, e041255.	0.8	0
263	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. Alzheimer's and Dementia, 2020, 16, e041500.	0.8	0
264	Quantifying the synaptic vesicleâ€associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e042717.	0.8	0
265	Transcriptome characterization of the motor cortex suggests microglialâ€related key events due to TDPâ€43 aberrant inclusions. Alzheimer's and Dementia, 2020, 16, e042953.	0.8	0
266	1 Hâ€MRS signature in Alzheimer disease in Down syndrome. Alzheimer's and Dementia, 2020, 16, e043346.	0.8	0
267	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. Alzheimer's and Dementia, 2020, 16, e043491.	0.8	0
268	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. Alzheimer's and Dementia, 2020, 16, e044772.	0.8	0
269	Which preâ€analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. Alzheimer's and Dementia, 2020, 16, e045060.	0.8	0
270	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimerâ€™s disease. Alzheimer's and Dementia, 2020, 16, e045268.	0.8	0

#	Article	IF	Citations
271	Bloodâ€based detection of earlyâ€stage Alzheimer using multiomics and machine learning. Alzheimer's and Dementia, 2020, 16, e047334.	0.8	0
272	Lateâ€onset epileptic seizures in adults with Down syndrome are linked to Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
273	Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The FundaciÃ³ ACE Biomarker Research Program (FACEBREP). Alzheimer's and Dementia, 2021, 17, .	0.8	0
274	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
275	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
276	Neuropsychological correlates of plasma NfL in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.8	0
277	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and populationâ€based study. Alzheimer's and Dementia, 2021, 17, .	0.8	0
278	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0
279	Transcriptome-wide characterization of the frontal cortex in FTLD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e049569.	0.8	0